Recent Updates
Recently added Catalysts
SIBN Neutral Sentiment

SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023

Key Takeaway: SI-BONE, Inc. announced it will disclose its financial results for the third quarter of 2023 on November 6, 2023, after market close. A conference call will be held immediately after the announcement for investors and stakeholders. The company, known for its surgical technology concerning musculoskeletal disorders, has a strong clinical backing and aims to provide insights into its financial performance.
Price reaction · baseline $17.14 (2023-10-13 close) · clean, no other SIBN news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in minimally invasive surgery technology.
  • The company has extensive clinical evidence supporting its technologies.
  • The upcoming financial results report may attract investor interest.

Full Press Release Details

SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/jw54nzhx. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 85,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its Q3 2023 financial results?

SI-BONE will report its financial results on November 6, 2023.

What time is the conference call for SI-BONE's Q3 results?

The conference call will start at 1:30 p.m. Pacific Time.

Where can I listen to the SI-BONE earnings call?

You can listen live on the company’s website or register online.

How long will the conference call webcast be available?

The webcast will be available for replay for at least 90 days.

What is SI-BONE known for?

SI-BONE specializes in minimally invasive surgical treatments for sacropelvic disorders.

Last updated: Oct 16, 2023